A Novel Mucilage from Ficus glomerata Fruits for Transdermal Patches: Taking Indomethacin as a Model Drug A novel mucilage from Ficus glomerata fruits
Iranian Journal of Pharmaceutical Sciences,
Vol. 7 No. 1 (2011),
15 January 2011
,
Page 25-36
https://doi.org/10.22037/ijps.v7.41349
Abstract
The present study was performed to explore the matrix property of Ficus glomerata fruit mucilage for making transdermal patches. The mucilage was evaluated for its physicochemical properties. Various transdermal patches of indomethacin were prepared by solvent evaporation technique using different proportions of F. glomerata fruit mucilage. The compatibility studies between indomethacin and F. glomerata fruit mucilage revealed that there were no negative interactions between indomethacin and the mucilage. The formulated patches were evaluated for physical properties, pre-formulary, post-formulary and skin irritation characteristics and they were found satisfactory. The experimental results shows that the drug release from the patches delayed in controlled manner as the proportion
of F. glomerata fruit mucilage increased. The accelerated stability studies proved that the formulated patches were stable at stressed storage conditions. It was concluded that F. glomerata fruit mucilage can be used as polymer for making transdermal patches.
- Ficus glomerata;
- Indomethacin;
- Transdermal patches.
How to Cite
References
[2] Rusu D, Cimpoiu C, Hodisan T. The control over the new obtaining procedeum of indomethacin. J Pharm Biomed Anal 1998; 17: 409-13.
[3] Claas SA, Glasser SP. Long-acting indomethacin for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Exp Opin Pharmacother 2005; 6: 765-76.
[4] Mark L, Woolfe, Martin F, Chaplin, Gifty Otchere. Studies on the mucilages extracted from okra fruits (Hibiscus esculentus L.) and baobab leaves (Adansonia digitata L.). J Sci Fd Agric 1971;28: 519-29
[5] Indian Pharmacopoeia, Govt. of India, Vol. 2, Controller of Publications, New Delhi, 1996; pp.A-100.
[6] Barry BW. Dermatological formulations: percutaneous absorption, drugs and pharmaceutical sciences. New York, Marcel Dekker, Inc. 1983: pp. 1-39.
[7] Sakalle P, Dwivedi S, Dwivedi Ab. Design, evaluation, parameters and marketed products of transdermal patches: a review. J Pharm Res 2010; 3: 235-40.
[8] Arora P, Mukherjee B. Development in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Res 2002; 91: 2076-89.
[9] Gupta R, Mukherjee B. Development and in vitro evaluation of indomethacin transdermal patches based on povidone-ethyl cellulose matrices. Drug Dev Ind Pharm 2003; 29: 1-7.
[10] Cleary GW. Transdermal delivery systems: a medical rationale, in: Topical drug bioavailability: bioequivalence and penetration. Shah VP and Maibach HI (eds), New York, Plenum, 1993: pp. 17-68.
[11] Draize JH, Woodward GS, Calvery HO. Method for the study of irritation and toxicity of substances applied topically to the skin and mucus membrane. J Pharmacol Exp Therap 1994; 82: 377-90.
[12] Remunan C, Bretal M, Nunez A, Bila Jato JL.Accelerated stability of sustained release tablet prepared with gelucire. Int J Pharm 1992; 80: 151-9.
- Abstract Viewed: 346 times
- IJPS_Volume 7_Issue 1_Pages 25-36 Downloaded: 231 times